The findings could lead to new treatments for blood cancers, which kill an estimated 23,540 people in the United States every year.

The distinction places her among the top 0.05% of scholars worldwide in her specialty, hypertension.

A new study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights approved drugs with potential cancer preventive effects.

In this area, treatment gaps affect up to 96% of patients, leaving millions without care. The project is funded by the National Institute of Neurological Disorders and Stroke of the NIH. 

This award honors a genetic counselor who “advances genetic counseling as a vital part of health care through education, research or public policy.

The study will go a long way to improving the early diagnosis and treatment of familial hypercholesterolemia, a common genetic driver of cardiovascular disease.

The discovery could improve safety of allopurinol for millions by expanding genetic screening.